TY - JOUR
T1 - Pancreas preservation with University of Wisconsin and celsior solutions
T2 - A single-center, prospective, randomized pilot study
AU - Boggi, Ugo
AU - Vistoli, Fabio
AU - Del Chiaro, Marco
AU - Signori, Stefano
AU - Croce, Chiara
AU - Pietrabissa, Andrea
AU - Berchiolli, Raffaella
AU - Marchetti, Piero
AU - Del Prato, Stefano
AU - Mosca, Franco
PY - 2004/4/27
Y1 - 2004/4/27
N2 - Background. Celsior is an extracellular-type, low-viscosity, preservation solution already used for heart, lung, liver, and kidney transplantation. We report the results of a single-center, prospective, randomized pilot study specifically designed to compare the safety profile of Celsior solution with University of Wisconsin (UW) solution in clinical pancreas transplantation. Methods. A total of 105 consecutive procurements were randomized to graft preservation with UW (n=53) solution or Celsior (n=52) solution. The groups were comparable with regard to all donor and recipient characteristics. Results. Five grafts were discarded and 100 grafts (50 UW vs. 50 Celsior) were transplanted. Mean cold and warm ischemia times were 11.0±2.1 hr and 37.2±6.0 min for UW compared with 10.8±1.8 hr and 38.1±5.9 min for Celsior (P=not significant). Delayed endocrine pancreas function was recorded in one graft preserved with UW solution. Eleven recipients (UW 12% vs. Celsior 10%, P=not significant) required a relaparotomy. The mean serum levels of glucose, amylase, and lipase remained comparable between the study arms at equivalent intervals after transplantation. One recipient died with functioning grafts in each study arm; two further grafts were lost to arterial thrombosis (Celsior) and chronic rejection (UW), respectively. Actuarial 1-year patient and graft survival rates overlapped in the two study arms (98% and 96%, respectively). Conclusions. Within the range of cold ischemia time reported in this study, UW and Celsior solutions have similar safety profiles for pancreas preservation.
AB - Background. Celsior is an extracellular-type, low-viscosity, preservation solution already used for heart, lung, liver, and kidney transplantation. We report the results of a single-center, prospective, randomized pilot study specifically designed to compare the safety profile of Celsior solution with University of Wisconsin (UW) solution in clinical pancreas transplantation. Methods. A total of 105 consecutive procurements were randomized to graft preservation with UW (n=53) solution or Celsior (n=52) solution. The groups were comparable with regard to all donor and recipient characteristics. Results. Five grafts were discarded and 100 grafts (50 UW vs. 50 Celsior) were transplanted. Mean cold and warm ischemia times were 11.0±2.1 hr and 37.2±6.0 min for UW compared with 10.8±1.8 hr and 38.1±5.9 min for Celsior (P=not significant). Delayed endocrine pancreas function was recorded in one graft preserved with UW solution. Eleven recipients (UW 12% vs. Celsior 10%, P=not significant) required a relaparotomy. The mean serum levels of glucose, amylase, and lipase remained comparable between the study arms at equivalent intervals after transplantation. One recipient died with functioning grafts in each study arm; two further grafts were lost to arterial thrombosis (Celsior) and chronic rejection (UW), respectively. Actuarial 1-year patient and graft survival rates overlapped in the two study arms (98% and 96%, respectively). Conclusions. Within the range of cold ischemia time reported in this study, UW and Celsior solutions have similar safety profiles for pancreas preservation.
UR - http://www.scopus.com/inward/record.url?scp=2342523325&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2342523325&partnerID=8YFLogxK
M3 - Article
C2 - 15114082
AN - SCOPUS:2342523325
VL - 77
SP - 1186
EP - 1190
JO - Transplantation
JF - Transplantation
SN - 0041-1337
IS - 8
ER -